Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE Study: Roflumilast in COPD
NCT00242320Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2005
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast with Placebo (2 arms). Primary endpoint: Mean change from randomization to endpoint in lung function (post bronchodilator) at 12 weeks. Started Aug 2005; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00242320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242320.